EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Efficacy of Disitamab Vedotin in Treating HER 2 2+/ FISH ‐Bladder Cancer: A Case Report

Zhi-Ruo Jin, Cheng-Yong Dong, Yu-Jun Li, Yang Zou, Xi-Mei Wang, Hui-Ying Li, Gang Wang, Xiao-Nan Cui iD, Ying Liu

Clinical Case Reports · 2026-06 · 14 (6)

DOI: 10.1002/ccr3.72855 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Clinical Case Reports, online erschienen am 21.06.2026. Verfasst von Zhi-Ruo Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Affiliated Zhongshan Hospital of Dalian University Dalian People's Republic of China. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disitamab Vedotin achieved durable partial response (> 8 months PFS) in advanced HER2 2+/FISH‐ bladder cancer after first‐line chemo‐immunotherapy progression. This case provides real‐world evidence that disitamab vedotin may benefit HER2 2+/FISH‐ patients, supporting broader HER2 testing and treatment consideration in this subset.

Schlagwörter

Stichwörter der Autor:innen

Disitamab Vedotin (RC48)antibody‐drug conjugates (ADCs)bladder cancerhuman epidermal growth factor receptor 2 (HER2)

Autor:innen und Institutionen

  • Department of Oncology Affiliated Zhongshan Hospital of Dalian University Dalian People's Republic of China.
  • Department of Hepatological Surgery The Second Affiliated Hospital of Dalian Medical University Dalian People's Republic of China.
  • Department of Oncology The First Affiliated Hospital of Dalian Medical University Dalian People's Republic of China.
  • The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor Dalian People's Republic of China.

ORCID-Profile: Xiao-Nan Cui

Zitieren

APA

Jin, Z. R., Dong, C. Y., Li, Y. J., Zou, Y., Wang, X. M., Li, H. Y., Wang, G., Cui, X. N., & Liu, Y. (2026). Efficacy of Disitamab Vedotin in Treating HER 2 2+/ FISH ‐Bladder Cancer: A Case Report. Clinical Case Reports, 14(6). https://doi.org/10.1002/ccr3.72855

Vancouver

Jin ZR, Dong CY, Li YJ, Zou Y, Wang XM, Li HY, et al. Efficacy of Disitamab Vedotin in Treating HER 2 2+/ FISH ‐Bladder Cancer: A Case Report. Clinical Case Reports. 2026;14(6). doi:10.1002/ccr3.72855

BibTeX
@article{Jin2026,
  author = {Jin, Zhi-Ruo and Dong, Cheng-Yong and Li, Yu-Jun and Zou, Yang and Wang, Xi-Mei and Li, Hui-Ying and Wang, Gang and Cui, Xiao-Nan and Liu, Ying},
  title = {Efficacy of Disitamab Vedotin in Treating HER 2 2+/ FISH ‐Bladder Cancer: A Case Report},
  journal = {Clinical Case Reports},
  year = {2026},
  volume = {14},
  number = {6},
  doi = {10.1002/ccr3.72855}
}
Kostenlos starten →